
Parent company Iolyx Therapeutics has announced plans to move into phase 3 trials of the investigative immunomodulator later in 2025.

Penny Asbell, MD, MBA, is a clinical professor of ophthalmology at UTHSC and external professor of biomedical engineering at the University of Memphis.

Parent company Iolyx Therapeutics has announced plans to move into phase 3 trials of the investigative immunomodulator later in 2025.